INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 01/12/23
PHAT INVESTOR ALERT: ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 01/12/23
PHAT Equity Alert: ROSEN, A Leading Law Firm, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATNewsfile Corp • 01/11/23
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)GlobeNewsWire • 01/08/23
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive EsophagitisGlobeNewsWire • 01/03/23
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 12/02/22
PHAT NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 11/23/22
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/08/22
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare ConferencesGlobeNewsWire • 11/03/22
PHAT LOSS ALERT: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 11/01/22
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing AgreementGlobeNewsWire • 11/01/22
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)GlobeNewsWire • 10/24/22
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific MeetingGlobeNewsWire • 10/23/22
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Phathom Pharmaceuticals, Inc. - PHATNewsfile Corp • 08/13/22
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 08/12/22
ROSEN, Global Investor Counsel, Encourages Phathom Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation - PHATNewsfile Corp • 08/09/22
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/08/22
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/05/22
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 08/05/22
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 08/05/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/04/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of InvestorsBusiness Wire • 08/03/22
